Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT Debt-to-EBITDA is 5.17 as of Dec. 2025, which is 1888% above its 10-year median of 0.26. The stock has 8 warning signs investors should review. Among 690 Drug Manufacturers companies, Vitura Health ranks worse than 67.68% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vitura Health's Debt-to-EBITDA or its related term are showing as below:
ASX:VIT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.85 Med: 0.26 Max: 2.95
Current: 2.95
During the past 7 years, the highest Debt-to-EBITDA Ratio of Vitura Health was 2.95. The lowest was -4.85. And the median was 0.26.
ASX:VIT's Debt-to-EBITDA is ranked worse than 67.68% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs ASX:VIT: 2.95
Vitura Health (ASX:VIT) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vitura Health Debt-to-EBITDA Related Terms
Vitura Health Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vitura Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vitura Health's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Vitura Health (ASX:VIT) has a Debt-to-EBITDA of 5.17 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vitura Health. This is 1888% above median its historical median of 0.26. According to the industry distribution chart, Vitura Health ranks #467 out of 690 companies in the Drug Manufacturers industry, placing it in the top 67.7%.
Is Vitura Health's Debt-to-EBITDA too high?
Vitura Health's current Debt-to-EBITDA of 5.17 is 1888% above median its 10-year median of 0.26. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Vitura Health's value of 5.17 is 207.7% above this industry median. Based on the distribution chart, Vitura Health ranks #467 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Vitura Health's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #467 out of 690 companies for Debt-to-EBITDA. This places Vitura Health in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Vitura Health's value of 5.17 is 207.7% above this benchmark. While the company's 10-year median is 0.26 vs. the industry median of 1.68, Vitura Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current Debt-to-EBITDA of 5.17 is 207.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vitura Health. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current Debt-to-EBITDA is 5.17, which is 1888% above median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 69% below its estimated fair value. The current Debt-to-EBITDA is 5.17, which is 1888% above median its 10-year median of 0.26 and 207.7% above the Drug Manufacturers industry median of 1.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current Debt-to-EBITDA is 5.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
